These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23911931)

  • 1. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
    Ahmed M; Sadek MM; Abouzid KA; Wang F
    J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
    Huang Y; Rizzo RC
    Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.
    Sato T; Watanabe H; Tsuganezawa K; Yuki H; Mikuni J; Yoshikawa S; Kukimoto-Niino M; Fujimoto T; Terazawa Y; Wakiyama M; Kojima H; Okabe T; Nagano T; Shirouzu M; Yokoyama S; Tanaka A; Honma T
    Bioorg Med Chem; 2012 Jun; 20(12):3756-67. PubMed ID: 22607878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of new anti-HER2 ligands using combined docking, QM/MM scoring and MD simulation.
    Ahmed M; Sadek MM; Serrya RA; Kafafy AH; Abouzid KA; Wang F
    J Mol Graph Model; 2013 Mar; 40():91-8. PubMed ID: 23353584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A possible strategy against head and neck cancer: in silico investigation of three-in-one inhibitors.
    Tsou YA; Chen KC; Chang SS; Wen YR; Chen CY
    J Biomol Struct Dyn; 2013 Dec; 31(12):1358-69. PubMed ID: 23140436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
    Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
    Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
    Awale M; Mohan CG
    J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
    Kamath S; Buolamwini JK
    J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
    Yu X; Wang T; Lou Y; Li Y
    Mol Inform; 2016 Jan; 35(1):25-35. PubMed ID: 27491651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR, HER2 target based molecular docking analysis, in vitro screening of 2, 4, 5-trisubstituted imidazole derivatives as potential anti-oxidant and cytotoxic agents.
    Guda R; Kumar G; Korra R; Balaji S; Dayakar G; Palabindela R; Myadaraveni P; Yellu NR; Kasula M
    J Photochem Photobiol B; 2017 Nov; 176():69-80. PubMed ID: 28964888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
    Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
    Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
    Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
    J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
    Yang B; Zhang H; Wang H
    J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating molecular dynamics-guided lead optimization of EGFR inhibitors.
    Lavecchia MJ; Puig de la Bellacasa R; Borrell JI; Cavasotto CN
    Bioorg Med Chem; 2016 Feb; 24(4):768-78. PubMed ID: 26810832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
    Park J; McDonald JJ; Petter RC; Houk KN
    J Chem Theory Comput; 2016 Apr; 12(4):2066-78. PubMed ID: 27010480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
    Al-Anazi M; Al-Najjar BO; Khairuddean M
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.